Liquidia secures up to $100M in additional financing from HCR for YUTREPIA commercialization

Liquidia Corp

$25M funded at closing; $50M contingent on first commercial sale of YUTREPIA after FDA approval for PAH/PH-ILD (no injunction).
Additional $25M available if YUTREPIA net sales exceed $100M by June 30, 2026, subject to mutual agreement.
Payments capped at 175% of amounts advanced; minimum IRR rates: 16%/13%/12% for three new tranches.
CFO: combination of proceeds and successful YUTREPIA launch could lead to profitability without additional capital.
Proceeds to fund YUTREPIA commercial development, clinical trials, L606 development, and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.